Can-Fite BioPharma (TASE:CANF) - Stock Price, News & Analysis

CANF Stock Overview

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction.

About the company

CANF fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Risk Analysis

Makes less than USD$1m in revenue ($743K)

Earnings are forecast to decline by an average of 3.5% per year for the next 3 years

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

+ 2 more risks

Can-Fite BioPharma Ltd. Competitors

Evogene

TASE:EVGN

₪129.1m

Kamada

TASE:KMDA

₪1.1b

Univo Pharmaceuticals

TASE:UNVO

₪2.8m

PlantArc Bio

TASE:PLNT

₪9.1m

Price History & Performance

Summary of all time highs, changes and price drops for Can-Fite BioPharma
Historical stock prices
Current Share Price	₪0.026
52 Week High	₪0.041
52 Week Low	₪0.021
Beta	0.91
1 Month Change	-7.14%
3 Month Change	0%
1 Year Change	18.18%
3 Year Change	-89.30%
5 Year Change	-97.08%
Change since IPO	-99.92%

Recent updates

Shareholder Returns

	CANF	IL Biotechs	IL Market
7D	0%	3.2%	2.9%
1Y	18.2%	4.6%	10.8%

Return vs Industry: CANF exceeded the IL Biotechs industry which returned 4.6% over the past year.

Return vs Market: CANF exceeded the IL Market which returned 10.8% over the past year.

Price Volatility

Is CANF's price volatile compared to industry and market?
CANF volatility
CANF Average Weekly Movement	4.8%
Biotechs Industry Average Movement	8.2%
Market Average Movement	4.4%
10% most volatile stocks in IL Market	8.3%
10% least volatile stocks in IL Market	3.1%

Stable Share Price: CANF has not had significant price volatility in the past 3 months.

Volatility Over Time: CANF's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1994	8	Motti Farbstein	www.canfite.com

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.

Can-Fite BioPharma Ltd. Fundamentals Summary

How do Can-Fite BioPharma's earnings and revenue compare to its market cap?
CANF fundamental statistics
Market cap	₪38.93m
Earnings (TTM)	-₪28.98m
Revenue (TTM)	₪2.82m

13.8x

P/S Ratio

-1.3x

P/E Ratio

Is CANF overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CANF income statement (TTM)
Revenue	US$743.00k
Cost of Revenue	US$0
Gross Profit	US$743.00k
Other Expenses	US$8.38m
Earnings	-US$7.63m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0051
Gross Margin	100.00%
Net Profit Margin	-1,027.46%
Debt/Equity Ratio	0%

How did CANF perform over the long term?

See historical performance and comparison

CANF Stock Overview

Rewards

Risk Analysis

Can-Fite BioPharma Ltd. Competitors

TASE:EVGN

₪129.1m

TASE:KMDA

₪1.1b

TASE:UNVO

₪2.8m

TASE:PLNT

₪9.1m

Price History & Performance

Recent News & Updates

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Recent updates

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.003 loss in 3Q 2022)

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Financial data availability

First half 2023 earnings released: US$0.004 loss per share (vs US$0.006 loss in 1H 2022)

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.003 loss in 1Q 2022)

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Insufficient new directors

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Second quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 2Q 2021)

Forecast to breakeven in 2023

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

First quarter 2022 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1Q 2021)

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel

Insufficient new directors

Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate

Can-Fite BioPharma Ltd. Announces Top Line Data from its Phase III Comfort™ Study of Piclidenoson in Treatment of Moderate-To-Severe Plaque Psoriasis to Be Release in the Second Quarter of 2022

We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

Can-Fite BioPharma Ltd. Announces Pre-Clinical Studies with Skin Cells, Modeling Psoriasis in Humans

Can-Fite Biopharma Ltd Files Patent Applications for the Treatment of Various Advanced Solid Tumors

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Can-Fite Biopharma Ltd. Announces Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Can-Fite Biopharma Ltd. Commences Clinical Study for the Treatment of Canine Osteoarthritis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?

Can-Fite BioPharma Ltd. Completes Patient Enrollment in Phase III Psoriasis Study

Second quarter 2021 earnings released: US$0.006 loss per share (vs US$0.013 loss in 2Q 2020)

Can-Fite BioPharma Ltd Receives Notice of Patent Allowance in China for NASH Treatment

No longer forecast to breakeven

Can-Fite Biopharma Ltd. to Initiate Phase IIb Nash Study with its Drug Candidate Namodenoson